Intermittent androgen suppression in the management of prostate cancer

Urology

Volumn 53, Issue 3, 1999, Pages 530-534

  Crook, J M ^a   Szumacher, E ^a   Malone, S ^a   Huan, S ^b   Segal, R ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FOLLOW UP; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS;

EID: 0033105250     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00547-0     Document Type: Article

References (17)

1. Labrie R., Dupont A., Belanger A., et al. New approach in the treatment of prostate cancer complete instead of partial withdrawal of androgen . Prostate. 4:1983;579-594.
2. Dijkman G.A., Janknegt R.A., De Reijke T.M., et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 158:1997;160-163.
3. Eisenberger M., Crawford E.D., McLeod D., et al. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. ASCO Proc. 16:1997;A3.
4. Prostate Cancer Trialists' Collaborative Group . Maximum androgen blockade in advanced prostate cancer an overview of 22 randomised trials with 3283 deaths in 5710 patients . Lancet. 346:1995;265-269.
5. Crawford E.D., Eisenberg M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
6. MRC Prostate Cancer Working Party . Immediate vs deferred treatment for advanced prostate cancer initial results of the MRC trial . Br J Urol. 79:1997;235-246.
7. Schellhammer P.F., Kuban D.A., El-Mahdi A.M. Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol. 150:1993;1851-1855.
8. Sandford N.L., Searle J.W., Kerr J.F.R. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology. 16:1983;406-410.
9. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50:1990;2275-2282.
10. Rennie P.S., Bruchovsky N., Coldman A.J. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Molec Biol. 37:1990;843-847.
11. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer. 71:1993;2782-2790.
12. Sato N., Gleave M.E., Goldenberg S.L., et al. Intermittent androgen suppression delays time to androgen-independent progression in the LNCaP prostate tumor model. J Urol. 153:1995;282a.
13. Klotz L.H., Herr H.W., Morse M.J., et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 58:1986;2546-2550.
14. Goldenberg S.L., Bruchovsky N., Gleave M., et al. Intermittent androgen suppression in the treatment of prostatic carcinoma an update . J Urol. 157:1997;333.
15. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report . Urology. 45:1995;839-845.
16. Higano C.S., Ellis W., Russel K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer a pilot study . Urology. 48:1996;800-804.
17. Bales GR, Sinner MD, Kim JH, et al: Impact of intermittent androgen deprivation on quality of life. AUA Annual Convention, Orlando, Florida, 1996.